Clinical Report: Preventing Blindness in Retinopathy of Prematurity

Overview

This report highlights key strategies for preventing blindness in retinopathy of prematurity (ROP), emphasizing the importance of ongoing monitoring and the use of anti-VEGF treatments. Aflibercept and bevacizumab are discussed as effective options, with a focus on timely follow-up care.

Background

Retinopathy of prematurity is a significant cause of visual impairment in preterm infants, making early detection and treatment crucial. The management of ROP has evolved with the introduction of anti-VEGF therapies, which offer rapid results compared to traditional laser treatments. Understanding the latest guidelines and treatment options is essential for healthcare professionals involved in pediatric eye care.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Ongoing monitoring of infants at risk for ROP is critical for preventing blindness.
• Aflibercept (Eylea) is an approved treatment in the U.S., while bevacizumab (Avastin) is commonly used off-label.
• Anti-VEGF treatments typically show regression of ROP within 48 hours, compared to 2 weeks for laser photocoagulation.
• Regular follow-up is necessary, especially around 60 weeks, to assess the need for continued treatment.
• Recent guidelines emphasize the importance of team-based approaches and telemedicine in ROP screening.

Clinical Implications

Retina specialists should prioritize regular examinations of at-risk infants to monitor disease progression. The choice between anti-VEGF and laser therapy should be guided by individual patient circumstances, with an emphasis on follow-up care to prevent recurrences.

Conclusion

Effective management of retinopathy of prematurity requires a combination of vigilant monitoring and appropriate treatment strategies. Continued education and adherence to updated guidelines will enhance outcomes for affected infants.

References

1. Retinal Physician, Prevent Blindness Declares Third Annual ROP Awareness Week, 2026 -- Prevent Blindness Declares Third Annual ROP Awareness Week
2. Ophthalmology Management, Prevent Blindness Announces Third Annual ROP Awareness Week, 2026 -- Prevent Blindness Announces Third Annual ROP Awareness Week
3. Eyecare Business, Prevent Blindness Declares Third Annual ROP Awareness Week, 2026 -- Prevent Blindness Declares Third Annual ROP Awareness Week
4. Retinal Physician, Guidelines for Preventing Blindness From Retinopathy of Prematurity, 2013 -- Guidelines for Preventing Blindness From Retinopathy of Prematurity
5. UK screening of ROP guidelines, 2024 -- UK ROP Screening Guidelines
6. Anti-VEGF versus laser therapy for retinopathy of prematurity: a systematic review and meta-analysis, 2025 -- Anti-VEGF versus laser therapy for retinopathy of prematurity
7. UK screening of
8. Anti-VEGF versus laser therapy for retinopathy of prematurity: a systematic review and meta-analysis focusing on recurrence patterns and retreatment needs - PMC
9. https://ranzco.edu/wp-content/uploads/2022/01/RANZCO-ROP-Guideline_2025.pdf